Two vaccines with excellent safety pass the first phase trials

The potential to develop the vaccine against the novel coronavirus pandemic, the Indian government shared that they are in touch with the vaccine manufacturing industry, who are doing their best to make a safe and effective Covid-19 vaccine at the earliest.

The Minister of State (Health and Family Welfare), Ashwini Kumar Choubey said that lockdown from March 25 to May 31 effectively controlled the aggressive progression of COVID in India.

He also said phase-I clinical trials have revealed “excellent safety” of the two candidate vaccines indigenously developed by Bharat Biotech in collaboration with ICMR and Cadila Healthcare Ltd and their immunogenicity testing is now in progress.

He also mentioned the development progress of COVID 19 vaccines. He said that the Central Drugs Standard Control Organisation (CDSCO) has granted test license permission for manufacture of vaccine for pre-clinical test, examination and analysis to the following manufacturers in India:

1) Serum Institute of India Pvt., Ltd., Pune

2) Cadila Healthcare Ltd., Ahmadabad

3) Bharat Biotech International Ltd., Hyderabad

4)Biological E Ltd., Hyderabad

5) Reliance Life Sciences Pvt Ltd., Mumbai

6) Aurobindo Pharma Limited, Hyderabad

7) Gennova Biopharmaceuticals Limited, Pune

The ICMR has allocated ₹25 crore for various studies and other research activities pertaining to vaccine development.

As per the World Health Organisation, 35 vaccine candidates are under clinical evaluation and 145 candidates are in pre-clinical evaluation stage as on September 9, Choubey said.

Leave a Reply

Your email address will not be published. Required fields are marked *